142 related articles for article (PubMed ID: 32308443)
1. Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.
Sakiyama E; Chinen Y; Tsukamoto T; Takimoto-Shimomura T; Kuwahara-Ota S; Matsumura-Kimoto Y; Shimura Y; Kobayashi T; Horiike S; Kuroda J
Infect Drug Resist; 2020; 13():1017-1021. PubMed ID: 32308443
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations.
Sadjadian P; Wille K; Griesshammer M
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114733
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis.
Tremblay D; King A; Li L; Moshier E; Coltoff A; Koshy A; Kremyanskaya M; Hoffman R; Mauro MJ; Rampal RK; Mascarenhas J
Leuk Lymphoma; 2020 Mar; 61(3):660-667. PubMed ID: 31711337
[TBL] [Abstract][Full Text] [Related]
4. Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance Review.
Anand K; Burns EA; Ensor J; Rice L; Pingali SR
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):18-23. PubMed ID: 31699655
[TBL] [Abstract][Full Text] [Related]
5. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib.
Adesola AA; Cozma MA; Chen YF; Srichawla BS; Găman MA
World J Hepatol; 2023 Nov; 15(11):1188-1195. PubMed ID: 38075009
[TBL] [Abstract][Full Text] [Related]
6. Necessity to screen and treat latent tuberculosis before ruxolitinib treatment-Ruxolitinib-associated disseminated tuberculosis: A case report and literature review.
Hirai N; Kasahara K; Yoshihara S; Nishimura T; Omori K; Ogawa Y; Ogawa T; Hishiya N; Suzuki Y; Yano H; Yoshikawa M; Mikasa K
IDCases; 2020; 21():e00892. PubMed ID: 32642438
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
8. Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera.
Lescuyer S; Ledoux MP; Gravier S; Natarajan-Amé S; Duval C; Maloisel F; Mauvieux L; Toussaint E; Fornecker LM; Herbrecht R
Int J Infect Dis; 2019 Mar; 80():134-136. PubMed ID: 30639623
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
Vaddi K; Verstovsek S; Kiladjian JJ
Blood Lymphat Cancer; 2016; 6():7-19. PubMed ID: 31360077
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.
Pepe S; Rossi E; Trawinska M; Tatarelli C; Di Veroli A; Maurillo L; Romano A; Crescenzi SL; di Toritto TC; Tafuri A; Latagliata R; Scalzulli E; Andriani A; De Stefano V; Breccia M
Ann Hematol; 2022 Jun; 101(6):1275-1282. PubMed ID: 35318505
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations.
Blum S; Martins F; Alberio L
J Blood Med; 2016; 7():205-215. PubMed ID: 27729820
[TBL] [Abstract][Full Text] [Related]
12. Unexpected Neurological Symptoms of Ruxolitinib: A Case Report.
Furia F; Canevini MP; Federici AB; Carraro MC
J Hematol; 2020 Dec; 9(4):137-139. PubMed ID: 33224394
[TBL] [Abstract][Full Text] [Related]
13. Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.
Chojecki A; Boselli D; Dortilus A; Hamadeh I; Begley S; Chen T; Bose R; Podoltsev N; Zeidan AM; Balmaceda NB; Yacoub A; Ai J; Knight TG; Ragon BK; Shah NA; Sanikommu SR; Symanowski J; Mesa R; Grunwald MR
Ann Hematol; 2024 Apr; ():. PubMed ID: 38662203
[TBL] [Abstract][Full Text] [Related]
14. Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review.
Peng Y; Meng L; Hu X; Han Z; Hong Z
Infect Drug Resist; 2020; 13():3309-3316. PubMed ID: 33061478
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes.
Cingam S; Flatow-Trujillo L; Andritsos LA; Arana Yi C
J Blood Med; 2019; 10():381-390. PubMed ID: 31814788
[TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative and lymphoproliferative disorders: State of the art.
Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase inhibitors: jackpot or potluck?
Pavithran K; Pande SB
Oncol Rev; 2012 Mar; 6(1):e13. PubMed ID: 25992203
[TBL] [Abstract][Full Text] [Related]
18. Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D; Mascarenhas J
Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
[TBL] [Abstract][Full Text] [Related]
19. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
Mesa RA; Scherber RM; Geyer HL
Leuk Lymphoma; 2015 Jul; 56(7):1989-99. PubMed ID: 25644746
[TBL] [Abstract][Full Text] [Related]
20. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
